MDCX vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 04, 2026
MDCX
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MDCX | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 21.0526 | Tie |
| PEG Ratio | 0 | 105.2003 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.0% | 5.3% | GSK |
| Earnings Growth | 0.0% | -69.5% | MDCX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 42.4/100 | 46.7/100 | GSK |
| Profit Margin | 0.0% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MDCX
NeutralMixed signals - no dominant trend phase, RSI 41
GSK
DistributionPrice near a flattening SMA50 (slope 0.4%) with fading momentum, RSI 48
Fundamentals Snapshot
| Metric | MDCX | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -0.8 | 10.0 |
| Trailing P/E | — | 16.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | — | 0.7% |
| Operating Margin | 0.0% | 0.3% |
| EPS | -2.66 | 3.15 |
| Dividend Yield | — | 0.04% |